Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER2 | P43116 | 18/20 | 0.59 |
| ▸ | PTGER4 | P35408 | 5/20 | 0.59 |
| ▸ | PTGER3 | P43115 | 11/20 | 0.56 |
| ▸ | PTGDR | Q13258 | 5/20 | 0.56 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.55 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.42 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.39 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22352609 | 1.00 | PTGER2 (0.59) | PTGER2PTGER4PTGER3PTGDRPTGER1 | |
| SCHEMBL19144203 | 0.85 | PTGER2 (0.65) | PTGER2PTGER4PTGER3PTGDRPTGER1 | |
| SCHEMBL13693092 | 0.85 | PTGER2 (0.65) | PTGER2PTGER4PTGER3PTGDRPTGER1 | |
| SCHEMBL14315052 | 0.83 | PTGER2 (0.61) | PTGER2PTGER4PTGER3PTGDRPTGER1 | |
| SCHEMBL13690121 | 0.83 | PTGER2 (0.65) | PTGER2PTGER4PTGER3PTGDRPTGER1 | |
| SCHEMBL13693088 | 0.83 | PTGER2 (0.65) | PTGER2PTGER4PTGER3PTGDRPTGER1 | |
| SCHEMBL14315051 | 0.82 | PTGER2 (0.66) | PTGER2PTGER4PTGER3PTGDRPTGER1 | |
| SCHEMBL13690126 | 0.82 | PTGER2 (0.62) | PTGER2PTGER4PTGER3PTGDRPTGER1 | |
| SCHEMBL13125487 | 0.82 | PTGER2 (0.60) | PTGER2PTGER4PTGER3PTGDRPTGER1 | |
| SCHEMBL13674241 | 0.81 | PTGER2 (0.65) | PTGER2PTGER4PTGER3PTGDRPTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286787-A1 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286787-A1 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | GLA, GUSB, GANAB | PTGER2 3210/4885PTGER4 2687/4885PTGER3 2745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.